Cardiogenic Shock Working Group Registry
(CSWG Trial)

Recruiting in Palo Alto (17 mi)

+15 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Recruiting

Sponsor: Tufts Medical Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

The Cardiogenic Shock Working Group is a multicenter registry where we collect de-identified clinical variables from the medical records and follow-up phone calls of shock patients from multiple institutions and centralize this data to a single registry for analysis of clinical outcomes.

Research Team

Claudius Mahr, DO

Principal Investigator

University of Washington

Jaime Hernandez-Montfort, MD

Principal Investigator

Cleveland Clinic Foundation-Florida

Daniel Burkhoff, MD PhD

Principal Investigator

CardioVascular Research Foundation

Reshad Garan, MD

Principal Investigator

Beth Israel Deaconess Medical Center

Eligibility Criteria

Inclusion Criteria

Patients must have cardiogenic shock.

PAPI < 1.0

Cardiac Power Output ≤ 0.6

See 6 more

Treatment Details

Interventions

Acute Mechanical Circulatory Support Devices (Mechanical Circulatory Support Device)
Inotrope (Inotrope)
Vasopressor (Vasopressor)

Participant Groups

1Treatment groups

Experimental Treatment

Group I: Cardiogenic Shock PatientsExperimental Treatment3 Interventions

Cardiogenic Shock patients eligible for this study are defined by at least one of the two categories below. 1. Patients have at least 2 of the following concurrently at any point during the index hospitalization: MAP \< 60mmHg or a \>30mmHg drop in MAP from baseline, SBP \< 90mmHg or a \>30mmHg drop in SBP from baseline, Pulse \> 100, Cardiac Index \< 2.2, Cardiac Power Output ≤ 0.6 or PAPI \< 1.0. 2. Patients require the use of at least 1 vasopressor, inotrope or acute mechanical circulatory support device to maintain values above the above targets.